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INTRODUCTION 
In India still pulmonary tuberculosis is prevalent and stays as one 
of the leading cause of death. The cause of the death in most of the 
terminally ill pulmonary tuberculosis patient is corpulmonale and 
related cardiac problem. With the increase in incidence of retro viral 
infection and diabetes the prevalence of multi drug resistant pulmonary 
tuberculosis is high .This leads to increase in the chances for the 
corpulmonale. 
In the rural areas poverty and malnutrition lead to increased 
incidence and prevalence of tuberculosis. In the urban areas exposure to 
the automobile gases and dust particles predisposes patients to 
pulmonary diseases and COPD in later life.  
COPD in the later stages lead to right ventricular dilatation and 
corpulmonale. The development and implementation of the national 
programs for the detection and treatment of the tuberculosis is trying to 
treat the disease in the early stage itself to prevent such corpulmonale in 
future. In this study we are going to find easy solution to diagnose the 
lung disease related cardiac problem in the early stage itself without 
making mistakes.  
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In corpulmonale patients right ventricular systolic dysfunction is 
recognized to occur and it has been proved in many studies. But the 
corpulmonale patients are symptomatic not only because of the lung 
pathology and right heart failure, but also due to left ventricular 
dysfunction in the form of left ventricular systolic and left ventricular 
diastolic dysfunction .The dilated right ventricle pushes the 
interventricular septum towards left ventricle and interferes with left 
ventricular filling, which lead onto diastolic dysfunction of left 
ventricle. The additional metabolic factors like hypoxia, hypercapnea 
and acidosis lead on to direct myocardial depressant action and produce 
myocardial dysfunction in both left and right ventricle. 
So picking up left ventricular systolic and left ventricular diastolic 
dysfunction in patients with corpulmonale using simple 
echocardiographic parameters helps us to better assessment and 
understanding of the patients. So treatment can be planned accordingly.  
Corpulmonale is an end stage disease of the heart due to many 
pulmonary diseases like pulmonary tuberculosis, COPD, interstitial lung 
disease, occupational diseases and others. The treatment for 
corpulmonale needs extra medication and diet restrictions. We are going 
to study about the changes made in the heart using echocardiography. 
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 In corpulmonale patients the echo window is bit difficult to view 
.so assessment of right ventricular systolic, left ventricular systolic and 
left ventricular diastolic dysfunction  in patients with corpulmonale 
using simple parameters like  mitral annular plane systolic excursion 
(MAPSE),mitral  annular systolic velocity(MASV), tricuspid annular 
plane systolic excursion(TAPSE) ,tricuspid  annular systolic 
velocity(TASV),and e propagation velocity  makes echocardiography 
more complete and  easy.  
These parameters are studied individually in many studies and 
results correlate well with left and right ventricular dysfunctions. In the 
out patients department the usage of these simple parameters help the 
physicians to assess the patients quickly also. we are going to compare 
these parameters with one another and going to prove their validity. 
So in this study we are going to study the prevalence of right 
ventricular systolic, left ventricular systolic and diastolic dysfunction as 
well as the utility of these simple and newer echocardiographic 
parameters in patients with corpulmonale. 
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AIMS & OBJECTIVES 
 
1. To study the utility of newer echocardiographic parameters like 
mitral annular plane systolic excursion, mitral  annular systolic 
velocity, tricuspid annular plane systolic excursion, tricuspid  
annular systolic velocity, and ‘e’ propagation velocity in 
identifying right ventricular systolic ,left ventricular systolic and 
diastolic dysfunction in patients with corpulmonale 
2. To study the prevalence of right ventricular systolic, left 
ventricular systolic and left ventricular diastolic dysfunction  in 
patients with corpulmonale 
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REVIEW OF LITERATURE 
Cor – Heart (Latin) and Pulmonale – of the Lungs (New Latin) 
Pulmonary Heart disease 
Chronic obstructive pulmonary disease (COPD), definition of 
GOLD is preventable and treatable disease with some significant extra 
lung pathology. Cor pulmonale was defined by the WHO in 1963 as 
“hypertrophy of the right ventricle resulting from diseases involving the 
physiology and or anatomy of the lungs, except when these pulmonary 
alterations are the result of diseases that primarily affect the left side of 
the heart, example as in congenital cardiac disease. 
COPD is one of the major causes of morbidity worldwide.  World 
Bank data tells that it is expected to move from 4th and 12th most 
frequent cause of mortality in 2000, to 3rd and 5th leading cause of 
mortality in 2020. COPD is associated with more effects on heart. 
Cardiovascular disease is responsible for 50% of all hospital admission 
and nearly one third of deaths. In more advanced disease heart problem 
is responsible for 20%–25% of all mortality in COPD. COPD affects 
lung blood vessels, right ventricle and left ventricle leading to 
development of pulmonary hypertension, cor pulmonale, right 
ventricular dysfunction, and left ventricular dysfunction also. 
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Echocardiography is a rapid, noninvasive and exact method to evaluate 
the right ventricular systolic function and filling pressure, tricuspid 
regurgitation, left ventricular function and functions of valve. Many 
studies have proved that echocardiographically arrived estimates of 
pulmonary arterial pressure co-relate closely with pressures measured 
by right heart catheter  
The Right Ventricle in Pulmonary Hypertension. 
The right ventricle is exposed to pressure overload by chronic 
corpulmonale from any cause. The initial adaptive response of right 
ventricular hypertrophy is followed later in life by right ventricular 
contractile dysfunction. Right ventricular dilatation follows to allow 
compensatory preload and maintain stroke volume in spite of reduced 
fractional shortening.  
 
 
 
 
 
Pathogenesis of pulmonary hypertension in COPD 
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 As contractility weakens, clinical evidence of right ventricular 
failure occurs, characterized by rise in filling pressures, diastolic 
dysfunction, and decreasing cardiac output, which is compounded by 
tricuspid regurgitation due to dilatation of right ventricular annulus and 
poor leaflet cooptation. The increased volume and pressure overload of 
the right ventricle also produce left ventricular diastolic dysfunction. 
Right ventricular function is very important determinant of survival in 
patients with pulmonary hypertension. 
Clinical Presentation 
Pulmonary hypertension in hypoxic lung diseases is common but 
usually mild to moderate in severity. Breathlessness is the most frequent 
symptom, but may not be helpful because breathlessness is so prevalent 
in this patient population.  
A change in breathlessness or the development of extra symptoms 
such as angina, dizziness, syncope, and pedal edema may suggest 
further evaluation. physical examination findings common in idiopathic 
pulmonary hypertension such as a right ventricular heave, loud 
pulmonary component of the S2, tricuspid regurgitant murmur, and RV 
S4 may also be masked by the presence of parenchymal pulmonary 
disease.  
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Severe pulmonary hypertension may lead to ascites and 
peripheral edema. Few patients with severe COPD may develop pedal 
edema in the absence of RV failure, the cause of which is hypercapnia, 
suggesting that an elevated carbon dioxide partial pressure may be 
responsible for sodium retention. Hypoxemia itself may cause renal 
vasoconstriction, thus reducing urinary sodium excretion and lead to 
pedal edema. 
In corpulmonale patients the right ventricular systolic and 
diastolic dysfunction recognized to occur. This concept is proved in 
many studies. Presence of pulmonary hypertension interferes with the 
right ventricular systolic and diastolic function. The dilatation of the 
right ventricle interferes with diastolic filling of left ventricle. This also 
leads to decreased left ventricular ejection fraction and finally systolic 
function of left ventricle is also affected.  
 In the 1996, Italian study on echocardiographic Doppler 
evaluation of left ventricular impairment in chronic corpulmonale 
concluded that left ventricular filling is compromised due to shift of 
interventricular septum towards left ventricle. This also concluded that 
severity of pulmonary hypertension also correlates with the severity of 
left ventricular diastolic dysfunction. It was published in 1996 June 
edition of CHEST journal. 
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 Right ventricular volume overload causes flat interventricular 
septum and the curvature is lost. Also in corpulmonale patients greater 
negative intrathoracic pressure is needed for the lungs to get inflated. 
This leads to increase in left ventricular after load. This increase in left 
ventricular after load also impairs left ventricular systolic function. 
Hypoxia interferes with intracellular calcium transport. 
So the left ventricular relaxation during diastole is greatly 
affected. In an Indian study published in Indian journal, the left 
ventricular function was assessed in three categories of patients. 
Category 1 (35 patients) patients had COPD only. Category ii (21 
patients) is COPD with corpulmonale but without ventricular failure  
and right ventricular dysfunction and category iii (14patients) is COPD 
with corpulmonale with right ventricular dysfunction   
The left ventricular ejection fraction was assessed in category iii 
(14patients) i.e. COPD with corpulmonale with right ventricular 
dysfunction. This was only on an average 45.6% in this category, but 
68.5% and 70.8% in category ii and category I patients respectively. 
This clearly implies that right ventricular dysfunction leads to left 
ventricular dysfunction soon. Hypercapnea and acidosis of 
corpulmonale still depress the left ventricular function by its suppressant 
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action on myocardium. The left ventricular function further leads to 
deterioration of corpulmonale due to metabolic and mechanical factors. 
The left ventricular failure even if subclinical leads to delay in expected 
improvement in overt right ventricular failure in corpulmonale patients. 
Also biventricular failure in corpulmonale patients leads to kind of 
refractory heart failure. 
Assessment of right ventricular systolic function using TAPSE 
(tricuspid annular plane systolic excursion) is validated in many studies. 
In one study published in European heart journal 2007 June, right 
ventricular systolic function was studied using TAPSE. This correlated 
well with the right ventricular systolic function. Also TAPSE decreased 
as the severity of the pulmonary hypertension increased. 
In another TAIWAN study published in 2007 February, right 
ventricular systolic function was studied in scleroderma patients. In this 
study TAPSE and right ventricular systolic function were calculated 
separately and compared. It showed excellent correlation between 
TAPSE and right ventricular ejection fraction. TAPSE of less than 
19.6mm was associated with right ventricular ejection fraction of less 
than 40% with very high specificity. 
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 In Indian heart journal 2009 January, TAPSE in normal subjects 
and in patients with right ventricular dysfunction was studied. This was 
correlated with fractional shortening and annular plane systolic velocity. 
The value of less than 17mm TAPSE was identified in patients with 
right ventricular dysfunction. 
 American journal of respiratory critical care medicine November 
2006 published prognostic value of TAPSE in patients with established 
pulmonary hypertension. The value of < 18mm was associated with 
significantly increased mortality. This study concluded with the result of 
TAPSE being the powerful indicator of right ventricular systolic 
function. 
 Another important marker of right ventricular systolic function is 
TASV (tricuspid annular systolic velocity).This is calculated by tissue 
Doppler method. Sample volume is placed in the lateral tricuspid 
annulus and systolic velocity is calculated. The normal value in person 
with intact right ventricular systolic function is >10 cm/sec.  
In one study conducted in Pittsburgh medical centre USA, 
TAPSE was compared with TASV. In this study TAPSE correlated well 
with TASV. But in this study TASV more than 10.5 cm/sec identified 
12 
normal person. From this study we can infer that TASV is as good as 
TAPSE and can be measured simultaneously and easily. 
In another Swiss study published in 2005 the tricuspid annulus 
systolic velocity of lateral annulus> 12cm/sec identified normal systolic 
function with right ventricular ejection fraction of >55%. TASV 
<9cm/sec in patients with right ventricular dysfunction was able to 
identify the problem correctly and right ventricular ejection fraction in 
this patients were between 30-55%. 
MAPSE (mitral annular plane systolic excursion) 
 For assessment of left ventricular systolic function, MAPSE 
(mitral annular plane systolic excursion) is used. It is the measure of 
longitudinal systolic function of the left ventricle. It is calculated by the 
following steps. 
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1. Two dimensional Apical four chamber  is viewed. 
2. M-mode line is placed on the lateral mitral annulus 
3. Distance between the end diastole and peak systole is measured. 
MAPSE (mitral annular plane systolic excursion) can be 
calculated in both medial and lateral mitral annulus and average can also 
be taken. The normal value for MAPSE (mitral annular plane systolic 
excursion) is more than 10 mm. This is very important tool and can be 
very sensitive than left ventricular ejection fraction in identifying the 
left ventricular function.  
A study published in European heart journal 2011 September 
compared 62 heart failure patients with preserved ejection fraction 
patients with vo2 max 18.6±5 ml/min/kg with normal persons. MAPSE 
(mitral annular plane systolic excursion) in these patients at rest was 
10.9±2.1. But in normal persons it was 12.1±2.2. With exercise the 
MAPSE in patient’s was12±2.2. But in normal persons it rose to 
16.2±2.7. So this study concluded that MAPSE (mitral annular plane 
systolic excursion) is a highly reliable and important tool in patients of 
heart failure with normal left ventricular ejection fraction. 
In the journal of cardiovascular magnetic resonance the cut off 
value for MAPSE and TAPSE has been published in the year 2012. For 
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males of age 35-50 years MAPSE is 12.8 ±7.3mm. For females of same 
age it is 15.7±7.1mm. 
For males of age 35-50 years TAPSE is 19.3 mm. For females of 
same age it is 20.4mm. In patients with decreased ejection fraction, 
MAPSE was less than 6 mm. 
 This study concluded that MAPSE has got accurate relationship 
with left ventricular ejection fraction. 
 In the American journal of echocardiography September 2012 a 
study of correlation of MAPSE with LVEF has been published. In this 
study MAPSE was calculated by untrained person and LVEF was 
calculated by experienced echocardiographer. 
 In patients with normal ejection fraction MAPSE >11mmfor 
females and >13mm for males were found .In patients with decreased 
ejection fraction MAPSE was <6mm. This had concluded that MAPSE 
has got accurate relationship between with left ventricular ejection 
fraction. many studies with MAPSE showed that the longitudinal left 
ventricular systolic function correlate well with other parameters for left 
ventricular systolic function 
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MASV (mitral annular systolic velocity)   
MASV (mitral annular systolic velocity) is measured by tissue 
Doppler method. The sample volume is placed in the lateral mitral 
annulus and the systolic velocity is calculated in c.m/sec. 
 
 
 
 
 
 
 In the journal of cardiovascular ultrasound 2010 march the 
MASV (mitral annular systolic velocity) is compared with left 
ventricular ejection fraction. Here the cutoff value was taken as 6.8 
c.m/sec. For the patients with left ventricular systolic dysfunction the 
value is less than 6.8cm/sec. In this study the left ventricular ejection 
fraction was calculated by three dimensional echocardiography. 
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In another study published in 2012 cardiovascular ultrasound 
journal MASV (mitral annular systolic velocity) was calculated in 
hypertensive patients with diastolic dysfunction. This showed decreased 
MASV (mitral annular systolic velocity) which is a marker of 
longitudinal left ventricular systolic function. In this study control group 
population without hypertension showed normal MASV (mitral annular 
systolic velocity). 
Mitral ‘e’ propagation velocity     
 
 
 
 
 
 
To assess the left ventricular diastolic dysfunction the mitral e 
propagation velocity is one of the parameters. It is calculated by 
following steps.  
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1. To obtain two dimensional echo apical four chamber view and 
apply color Doppler at the mitral valve. 
2.  Then the M-mode line is placed on the line of color flow between 
mitral valve and left ventricular apex. 
3.  The early diastolic E flow is recorded and the Nyquist limit is 
adjusted as though no aliasing occur. 
4.  The velocity in the early phase of diastole i.e. the ‘e’ slope 
velocity is recorded. 
The normal value for ‘e’ propagation velocity is >50cm/sec. 
 The values of ‘e’ propagation velocity more than 50cm/sec 
indicates that there is good diastolic flow from LA to LV and also 
indicate intact diastolic function of the ventricle. The value of ‘e’ 
propagation velocity less than 50 cm/sec indicates left ventricular 
diastolic dysfunction.  
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 There is also correlation between ‘E’ peak velocity and Vp 
propagation velocity. The ratio of E/Vp more than 2.5 indicates raised 
pulmonary capillary wedge pressure more than 15 mmHg. 
In a study conducted in Poland in 2006 by Krystian Wite et al, 
Propagation velocity was calculated in patients with known diastolic 
dysfunction. The patients with diastolic dysfunction are categorized into 
three groups. The third group comprised of Grade 3 diastolic 
dysfunction. These patients had more decreased propagation velocity 
and increased pro-BNP level. 
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 In European respiratory journal 2008, LV diastolic dysfunction 
was studied in idiopathic pulmonary fibrosis patients. In this study the 
mitral inflow reversal was noted in all the patients and diastolic function 
was assessed by ‘e’ propagation velocity was 46±13 cm/sec which was 
higher in normal individuals of about 83±21 cm/sec. 
In Chest journal 2003, Cystic fibrosis patients are studied for RV 
and LV function. In the 40 patients studied all of them showed RV 
systolic dysfunction and LV diastolic dysfunction. But LV systolic 
function was not significantly decreased in these groups. 
 In 2006 Serbia Cardiovascular clinics of the Clinical centre NIS, 
50 patients with chronic cor pulmonale were studied for LV diastolic 
function and the results were compared with 56 patients of COPD 
without heart failure. 
 In conclusion, that the LV diastolic dysfunction was due to the 
progression of the right heart failure due to cor pulmonale and it 
indicates advanced disease. 
 In an Indian study conducted in Rajasthan in 2009, COPD 
patients were completely studied for Right and Left ventricular 
functions using Echocardiography. Among them, 2/3 of the patients had 
pulmonary hypertension and tricuspid regurgitation. The LV systolic 
dysfunction was seen in <10% of the cases and left ventricular diastolic 
dysfunction was found in almost half number of the cases. This study 
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also concluded the fact that echocardiography is extremely useful in 
early detection of cardiac complication in COPD patients. 
 In Turkish study 30 patients of Sarcoidosis were studied for 
cardiac involvement by echocardiography method. Among them, 
sixteen patients showed LV diastolic dysfunction even if there is no 
clinical proof of it. It was in the form of reversal of E/A ratio. This 
figure of more than 50% of LV diastolic dysfunction was very 
significant when compared to previous studies. 
 In our study, Cor pulmonale patients are studied by newer 
echocardiographic methods, unlike the previous studies. This enables us 
to detect the abnormality easily and accurately. 
 Traditionally, Cor pulmonale patients are defined by increase in 
bulk of the right ventricle due to lung pathology. The lung pathology in 
our group varied from chronic bronchitis, emphysema, old pulmonary 
tuberculosis, previous lung surgery and bronchiectesis.  
Interstitial Lung Disease 
     Diffuse parenchymal lung diseases (DPLDs) have also been 
linked with cor pulmonale. DPLDs are a heterogeneous group of 
diseases with similar clinical, x-ray, and physiological manifestations. 
This disease results in alterations in the alveolar walls, perialveolar 
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tissue, and other supporting structures. Occupational and environmental 
exposures can lead to DPLD, although frequently the cause is Not clear. 
The prevalence of pulmonary hypertension in patients with DPLDs 
varies widely.  
As in COPD, investigating method and criteria contribute to the 
variability between studies, with prevalence tending to be higher where 
echocardiography was used. Studies of persons undergoing evaluation 
for lung transplantation have clearly demonstrated a higher prevalence. 
Destruction and obliteration of the blood vessels secondary to loss of 
lung parenchyma and fibrosis plays a role. Studies of IPF have reported 
loss of blood vessels in areas of honeycomb lung and decrease in the 
mean capillary surface area.  
Vessel compression may lead to in situ thrombosis, fibrous 
organization of blood vessels, and luminal obliteration. Abnormal 
connections between the pulmonary and systemic circulation have also 
been identified in patients with IPF.  
 Cor pulmonale is right ventricular enlargement due to high 
resistance or pulmonary hypertension. Chronic increase in pulmonary 
arterial pressure leads to right ventricular hypertrophy. 
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Pulmonary tuberculosis with corpulmonale 
In Indian subcontinent still pulmonary tuberculosis is prevalent 
and stays as one of the leading cause of corpulmonale. With the increase 
in incidence of HIV infection and diabetes the prevalence of drug 
resistant pulmonary tuberculosis is high .This leads to increase in the 
chances for the corpulmonale .Immunodeficient states makes patient 
susceptible to chronic infection and so the incidence of infection to 
other people also increases. 
In the rural areas poverty and malnutrition lead to increased 
incidence of the tuberculosis. In the urban areas exposure to the 
automobile gases and dust particles predisposes patients to pulmonary 
diseases. Silicosis which is a occupational disease leads to pulmonary 
tuberculosis. In tuberculosis the development of the corpulmonale is due 
to decrease of lung elasticity, parenchymal pathology, alteration in the 
diffusion capacity, obstruction of the bronchial tree due to brochospasm 
and destruction of the lung tissue. 
The development of right ventricular enlargement takes many 
years to develop in corpulmonale patients. Smoking which is a risk 
factor for the development of the COPD is also a risk factor for the 
development of the coronary artery disease. So both of them co exist in 
24 
smokers. Presence of coronary artery disease in the COPD patients lead 
on to left ventricular systolic and diastolic dysfunction. 
DYSPNEA IN COPD 
 The grade of dyspnea in COPD increases in patients with 
corpulmonale if coronary artery disease co exists. The development of 
the corpulmonale lead to the state of irreversible disease process and 
patients worsen day by day if the precipitating lung pathology is not 
relieved. Ascites in corpulmonale lead to elevation of the diaphragm and 
worsening of the dyspnea. Pleural effusion caused by the right heart 
failure still increase the grade of dyspnea. 
Most of the previous studies are done in particular subset of 
patients with similar lung pathology and with only old 
echocardiographic parameters. Some parameters like RV tei index, RV 
ejection fraction and LV pulmonary flow reversal are not only time 
consuming and also difficult to view and interpret in already sick cor 
pulmonale patients. 
 So there is need for easier and simpler parameters like MAPSE, 
MASV, TASV, TAPSE and ‘e’ propagation velocity are very much in 
our setup. So we are going to study these in detail in this study. 
25 
MATERIALS AND METHODS 
All patients of corpulmonale referred for the study of the heart by 
echocardiography are taken for the study and included. The patients 
were selected irrespective of the lung pathology that caused 
corpulmonale. Both male and female patients are selected for the study. 
There was no age limit in our study population. Patients with 
acute corpulmonale were not included because of the acute symptoms.  
 Relevant history, clinical examination, X ray chest, E.C.G was 
taken for all the patients. Pulse oximetry, pulse rate, systolic and 
diastolic blood pressure and respiratory rate were taken.  
All the patients underwent detailed echocardiographic study. 
Echocardiogram was done using Philips HD7XE Echocardiographic 
machine. The following echocardiographic parameters were done. 
Mitral annular plane systolic excursion (MAPSE), Mitral  annular 
systolic velocity(MASV), Tricuspid annular plane systolic 
excursion(TAPSE), Tricuspid  annular systolic velocity(TASV),and ‘e’ 
propagation velocity  and  E/A ratio  were taken. TAPSE <17mm, 
MAPSE < 10mm, TASV < 10cm/s, MASV <7 cm/s and ‘e’ propagation 
velocity <50cm/s were taken as cut-offs for abnormal values as per 
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American Society of Echocardiography recommendations. Pulmonary 
hypertension was graded as mild, moderate and severe based on the 
tricuspid regurgitation pressure gradient on the echocardiography. 
 
INCLUSION CRITERIA:   
All patients of Corpulmonale evaluated in Department of 
Cardiology, Rajiv Gandhi Government General, Madras Medical 
College, Chennai 
 
EXCLUSION CRITERIA 
1. Patients with past history of CABG 
2. Patients with PTCA. 
3. Patients with valvular heart disease. 
4. Patients with hepatic dysfunction. 
5. Patients with a major non-cardiovascular disease. 
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6. Unwilling to give consent.  
7. Patients with coronary artery disease 
8. Patients with systemic hypertension 
9. Patients with LV dysfunction of any cause  
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RESULTS AND DATA ANALYSIS 
   40 patients of established cor pulmonale were 
selected for the study. Among them 23 were males and 17 were females. 
All are having right ventricular enlargement due to lung pathology. 
Among them 30 patients have COPD, 8 patients have old pulmonary 
tuberculosis and 2 patients have interstitial lung disease. The COPD 
comprises of 75 % of study population; 20% of cases are old pulmonary 
tuberculosis and 5% of cases are interstitial lung disease patients. 
Age of the patients ranged from 29 years to 70 years with the 
mean value of age is 49.5 years. Among female patients age range from 
29 years to 68 years with the mean age of 48.5 years. For the male 
patients it ranged from 29 years to 70 years with mean age of 49.5 years. 
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Table 1: Age and Sex distribution of Study Population 
Age 
Group 
Male Female Total 
No of  
Patient 
% 
No of 
Patients 
% 
No of 
Patients 
% 
< 30 1 4.3 1 5.9 2 5 
31- 40 6 26.1 4 23.5 10 25 
41 -50 6 26.1 4 23.5 10 25 
51 – 60 6 26.1 6 35.3 12 30 
61 – 70 4 17.4 2 11.8 6 15 
Total 23 100 17 100 40 100 
Mean ± S 
D 
49.0 ± 11.38 49.52 ± 10.9 49.22 ± 11.04 
 
Among the male patients corpulmonale is more common in the 
age group between 30-60 years of age .corpulmonale is less common 
before 30 years of age in both males and females. In female gender high 
prevalence was noted between 50-60 years of age. In the age group of 
60-70 years corpulmonale is slightly higher in the females when 
compared to males.  
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Among these 40 patients 18 patients had mild pulmonary 
hypertension, 8 patients had moderate pulmonary hypertension and14 
patients had severe pulmonary hypertension. These comprises of 45% of 
patients with mild pulmonary hypertension, 20% of patients with 
moderate pulmonary hypertension and 35% of patients with severe 
pulmonary hypertension. 
Table 2: Severity of Pulmonary Hypertension  
Pulmonary 
Hypertension 
Male Female Total 
No of  
Patient 
% 
No of 
Patients 
% 
No of 
Patients 
% 
Mild 9 39.13 9 52.94 18 45 
Moderate 5 21.74 3 17.64 8 20 
Severe 9 39.13 5 29.42 14 35 
Total 23 100 17 100 40 100 
 
The prevalence of mild pulmonary hypertension is more in 
females. The severe pulmonary hypertension prevalence is more in the 
males. This severe pulmonary hypertension being more common in 
males is probably due to increased smoking in the males. In the study 
population also males are more commonly affected than the females 
because of the same reason.  
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TAPSE of < 17mm was taken as having right ventricular systolic 
dysfunction in our study. 38 out of 40 patients had TAPSE of <17 MM. 
so prevalence of TAPSE calculated right ventricular systolic 
dysfunction is 95 % in our study. 5 % of patients were not having right 
ventricular systolic dysfunction when TAPSE was taken as the 
echocardiographic parameter. TASV of < 10 cm/sec was taken as 
having right ventricular systolic dysfunction in our study. 36 out of 40 
patients had TASV of <10 cm/sec. so prevalence of TASV calculated 
right ventricular systolic dysfunction is 90 % in our study. 10 % of 
patients were not having right ventricular systolic dysfunction when 
TASV was taken as the parameter. 
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 TAPSE (tricuspid annular plane systolic exertion) 
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TASV (tricuspid annular systolic velocity)  
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  MAPSE (mitral annular plane systolic exertion) 
 
 
 
 
 
 
 
 MAPSE is considered to represent left ventricular systolic 
dysfunction when it is <10mm in our study. MAPSE was < 10mm in 8 
out of 40 patients. So prevalence of MAPSE calculated left ventricular 
systolic dysfunction is 20 % in our study. 80 % of patients were not 
having left ventricular systolic dysfunction when MAPSE was taken as 
the echocardiographic parameter. 
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MASV (mitral annular systolic velocity) 
 
 
MASV of < 7 cm/sec was taken as having left ventricular systolic 
dysfunction in our study. 5 out of 40 patients had MASV of <7cm/sec. 
so prevalence of MASV calculated left ventricular systolic dysfunction 
is 12.5 % in our study. 87.5 % of patients were not having left 
ventricular systolic dysfunction when MASV was taken as the echo 
parameter. 
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‘e’ propagation velocity 
‘e’ propagation velocity of <50 cm/sec is taken as having left 
ventricular diastolic dysfunction in our study. 18 out of 40 patients had 
‘e’ propagation velocity of <50 cm/sec. so prevalence of e propagation 
velocity calculated left ventricular diastolic dysfunction is 45 % in our 
study. 55 % of patients were not having left ventricular diastolic 
dysfunction when e propagation velocity was taken as the echo 
parameter. 
 When E/A ratio is taken as echo parameter, to calculate left 
ventricular diastolic dysfunction in our study, 22 out of 40 patients had 
left ventricular diastolic dysfunction. So prevalence of E/A ratio 
calculated left ventricular diastolic dysfunction is 55 % in our study. 45 
% of patients were not having left ventricular diastolic dysfunction 
when E/A ratio were taken as the echo parameter. 
 An average of about half of the study population had left 
ventricular diastolic dysfunction. 
 
 
  
  Mild pulmonary hypertension is more prevalent in the study patients     
 
 
20%
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45%
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e
57%
Sex Distribution
Male
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Male are more affected than the females.
Prevalence of RV systolic 
TAPSE and TASV are more reliable 
well with the right ventricular systolic dysfunction. Their sensitivity and 
specificity in identifying the problem was very high. They can detect 
even subtle problem which other parameters cannot do 
simple parameters are proved useful in the acute set up also like right 
ventricular infarction in various studies.
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TAPSE
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Prevalence of LV systolic dysfunction 
Assessment of LV sy
important for the evaluation of the dyspnea. sudden deterioration in the 
dyspnea is due to the progressive worsening of the systolic 
In our study patients with 
prevalence of the LV systolic dysfunction.
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stolic dysfunction in corpulmonale is very 
dysfunction. 
severe pulmonary hypertension have more 
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Comparison of ‘e’ PV and E/A ration in detecting LV DD
compared to e propagation 
diastolic dysfunction is 
Comparing RV and LV systolic dysfunction in cor pulmonale
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. When 
 
  
 
TAPSE assess longitudinal right ventricular systolic dysfunction and its 
calculation detects many patients with early systolic dysfunction .
left ventricular systolic dysfunction which occur very late in the course 
of the disease is not that common when compared to right ventricular 
systolic dysfunction. These two parameters are derived 
echocardiography.  
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But 
-mode 
Tissue Doppler derived
the true state of the systolic functions of the right and left ventricle 
respectively. These results almost similar to results derived by other 
parameters. 
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TASV
MASV
In patients with chronic corpulmonale both systolic
dysfunction of the left 
patients had both systolic
They are more symptomatic than the patients with only diastolic 
dysfunction. 
The patients without even left
almost half of the study population. They are better 
dyspnea and symptoms.
 
 
 
50%
Incidence of LV Systolic and Diastolic 
 and diastolic 
ventricle co exist .In our study 20% of the 
 and diastolic dysfunction of the left ventricle. 
 ventricular diastolic dysfunction make up 
in the 
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grade of 
 Comparison of LV and RV dysfunction
In chronic cor pulmonale 
dysfunction, Left ventricular dysfunction is rare. But some form of left 
ventricular diastolic dysfunction co exist in almost half of the cor 
pulmonale cases. Left ventricular diastolic dysfunction is common 
malfunction than the systolic dysfunction. 
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RV Systolic
LV Diastolic
LV Systolic
  
 In our study, most common cause for cor pulmonale is COPD followed 
by old pulmonary tuberculosis. Interstitial lung diseases constitute about 
5% of the cor pulmonale population. 
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DISCUSSION 
This study was undertaken to establish the role of simple and 
useful parameters like TAPSE, TASV, MAPSE, MASV and e 
propagation velocity in patients with corpulmonale. Also in this study 
we aimed to study the prevalence of left ventricular systolic and 
diastolic dysfunction in corpulmonale cases. 
 TAPSE is a simple method when compared to RVEF and RV TEI 
index for studying right ventricular systolic dysfunction .It reliably 
detects right ventricular systolic dysfunction and the value decreased as 
the severity of systolic dysfunction worsen. Right ventricular systolic 
dysfunction was very much in patients with severe pulmonary 
hypertension when compared to mild pulmonary hypertension.  
 TASV is another newer parameter which utilizes tissue Doppler 
to assess the right ventricular systolic dysfunction. The value of 
<10cm/sec was taken as the cut off value .It correlated well with the 
TAPSE in identifying the right ventricular systolic dysfunction. It is 
well known that diseases like chronic bronchitis, pulmonary 
tuberculosis, emphysema, bronchial asthma, interstitial lung diseases 
and occupational diseases cause corpulmonale. But in our study COPD, 
47 
pulmonary tuberculosis and interstitial lung diseases were the diseases 
that caused the corpulmonale. 
 In tuberculosis cause for the development of the corpulmonale 
include decrease in the lung elasticity, parenchymal disease, and 
decrease in the diffusion capacity of the lung, obstruction of the 
bronchioles due to brochospasm and destruction of the lung tissue. 
 Development of the corpulmonale leads to terminal stage of the 
disease process and patient may go for congestive cardiac failure. 
Biventricular failure in pulmonary tuberculosis patients can be easily 
detected by echocardiography method using simple parameters like 
MAPSE,TAPSE,MASV and TASV. 
 MAPSE and MASV which is used to study the left ventricular 
function in our study are well accepted echo parameters. In future these 
parameters may replace the conventional methods. They can be 
compared with  many other parameters for the similar purposes. 
 The concept that the left ventricular dysfunction which was 
believed not to occur with corpulmonale patients is now disproved. In 
our study almost half of the patients had left ventricular diastolic 
dysfunction and 10-20 % of cases had left ventricular systolic 
dysfunction. So patients with corpulmonale definitely need 
48 
echocardiographic evaluation for the complete understanding about the 
symptoms.  
 In corpulmonale cases sudden worsening of symptoms may be 
due to the development of left ventricular systolic dysfunction. So 
physician must be watchful about this problem.  
 It is also clear from the study that the above said echo parameters 
are non inferior and can be used in routine echocardiographic evaluation 
of cardiac patients. When there is doubt regarding the right and left 
ventricular function, various parameters can be compared and doubts 
can be clarified. 
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 LIMITATIONS OF THE STUDY  
1. The study does not include the acute corpulmonale patients 
2. The COPD patients without obvious right ventricular and right 
atrial enlargement are not included in the study. So prevalence of 
the right ventricular and left ventricular dysfunction in those 
patients needs further evaluation 
3.  Right ventricular diastolic dysfunction which may be a earlier 
change in COPD was not included in the study. 
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CONCLUSION 
1. Left ventricular diastolic dysfunction occurred in about 50% of 
the corpulmonale patients. 
2. Left ventricular systolic dysfunction was observed in 10-20% 
percent in the study which is higher than the published literature. 
3. MAPSE and MASV are  simple and useful parameter to assess 
the left ventricular systolic dysfunction.  
4. TAPSE and TASV are simple and useful index in corpulmonale 
patients to assess right ventricular systolic dysfunction. 
5. It is found that atleast some amount of right ventricular systolic 
dysfunction was detected when the newer echocardiographic 
parameters  were used in most of the corpulmonale patients. 
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MASTER CHART 
S. NO Patient No. Sex Age PHT Severity TRPG TAPSE TASV MAPSE MASV e PV E/A DD Diagnosis 
1 Balamurugan M 36 Mild 30 15 8 11 10 52 0.8 1 PT 
2 Neela F 40 Mild 32 15 9 11 8 70 0.7 1 PT 
3 Kumaraguru M 61 Severe 64 16 8 11 7 43 0.8 1 COPD 
4 Muralidharan M 56 Severe 87 12 9 8 7 39 1.1 2 COPD 
5 Savithri F 45 Moderate 44 14 8 9 5.2 40 1.2 2 PT 
6 Ismail M 48 Moderate 52 14 9 12 9.5 38 0.9 1 COPD 
7 Hemavathy F 59 Severe 67 13 5.5 13.5 10 34 0.9 1 COPD 
8 Kumaran M 43 Mild 33 16 8 13 10 68 1.1 0 COPD 
9 Arumugam M 64 Severe 69 13 6.1 6.8 5.5 39 1.1 2 COPD 
10 Chithra F 49 Mild 33 14 8 11 10 52 1.2 0 PT 
11 Ramakrishnan M 51 Mild 35 16 9 11 8 51 1.1 0 COPD 
12 Selvi F 58 Severe 72 13 9 11 8 40 0.8 1 COPD 
13 Gowrishankar M 44 Moderate 40 15 8 11 8 45 0.9 1 COPD 
14 Anandhan M 46 Severe 77 12 8 10 7 33 1.1 2 COPD 
15 Shanmugam M 39 Mild 31 16 9 11 10 84 1.2 0 COPD 
16 Annakili F 40 Severe 65 14 7 8 8 43 0.9 1 COPD 
17 Dhandapani M 33 Mild 34 16 9 12 8 56 1.2 0 PT 
18 Bhuvana F 35 Mild 35 20 15 11 9 96 1.3 0 COPD 
19 Vedharajan M 59 Mild 32 16 13 10 8 64 1.1 0 COPD 
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20 Kanagavalli F 60 Moderate 53 16 7 10 7.5 46 1.1 0 COPD 
21 Palaniappan M 44 Mild 32 15 8 11 10 52 1.1 0 COPD 
22 Catherine F 49 Mild 33 16 9 11 8 70 1.1 0 COPD 
23 Govindaraj M 38 Severe 64 16 8 10 7 43 0.8 1 PT 
24 Ponniammal F 54 Severe 80 14 9 8 7 39 1.1 2 COPD 
25 Kandasamy M 70 Moderate 44 13 8 10 6 40 1.2 2 COPD 
26 Murugaselvan M 56 Moderate 52 16 9 12 9 38 0.9 1 COPD 
27 Manoharan M 69 Severe 63 15 5.5 13 10 34 0.9 1 PT 
28 Pushpammal F 64 Mild 31 16 8 13 10 68 1.1 0 COPD 
29 Murugan M 59 Severe 64 15 6.1 6 5.1 39 1.1 2 COPD 
30 Malathy F 44 Mild 33 16 8 11 10 52 1.1 0 COPD 
31 Kannagi F 38 Mild 35 15 9 12 8 51 1.1 0 COPD 
32 Sasikumar M 39 Severe 70 12 9 9 8 40 0.8 1 PT 
33 Fathima F 56 Moderate 48 15 8 12 8 45 1.2 0 COPD 
34 Abdul Khadar M 53 Severe 74 12 7 10 6.5 33 1.1 2 COPD 
35 Valli F 54 Mild 30 16 9 11 10 84 1.2 0 COPD 
36 Krishna Veni F 29 Severe 64 13 6 9 8 43 0.9 1 PT 
37 Radha F 68 Mild 34 16 9 10 8 56 1.2 0 COPD 
38 Dhayalan M 29 Mild 33 28 15 11 9 96 1.3 0 COPD 
39 Joseph M 40 Mild 32 15 13 10 8 64 1.1 0 COPD 
40 Muniappan M 50 Moderate 57 16 7 10 7.5 46 0.9 1 COPD 
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                                      ABBREVIATIONS AND ACRONYMS 
RV  - Right Ventricle 
LV  - Left Ventricle 
MAPSE - Mitral Annular Plane Systolic Excursion 
TAPSE - Tricuspid Annular Plane Systolic Excursion 
MASV - Mitral Annular Systolic Velocity 
TASV  - Tricuspid Annular Systolic Velocity 
LVEDD - Left Ventricle End Diastolic Dimension 
LV ESD - Left Ventricle End Systolic Dimension 
EF  -  Ejection Fraction 
RVEDD - Right Ventricle End Diastolic Dimension 
RVESD - Right Ventricle End Systolic Dimension 
RVFWT - Right Ventricle Free Wall Thickness 
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PROFORMA 
Name: 
Age:  
Sex:  
Address:   
 
CD No. : 
SYMPTOMS: 
Chest pain: 
SOB Class: 
Palpitations 
Right heart failure symptoms- 
 
Risk Factors 
h/o pul.TB                                                  Diabetes Mellitus 
Smoking                                                    Family History 
OCCUPATION                                    CONNECTIVE TISSUE DISORDERS 
15 
Past History: 
Treatment History 
 
Physical Examination 
1. General Examination 
2. Vital Signs 
 B.P     Pulse 
 Respiration                                         JVP Height cm Waveform 
 
3. Systemic Examination 
CVS 
Inspection / Palpation 
 Apex                                                                         Parasternal Heave 
 Palpable Sounds                                                     Thrills 
Auscultation 
  S1             S2                                                       Murmurs 
Extra Heart Sounds 
16 
Other System 
RS:                                PA:                                                      CNS: 
ECG: 
CHEST X-RAY PA VIEW 
 
   
ECHOCARDIOGRAPHIC ASSESSMENT OF corpulmonale 
Name:                                                      Age:                                             Sex: 
Echocardiographic parameters: 
M-mode: 
LV:                 EDD-                     ESD-                     EF-                   FS- 
  MAPSE 
RV:                 RVFWT                                      RVEDD             TAPSE        
   
Mitral valve: 
Aortic valve:     LVOT diameter: 
LA: 
17 
Tricuspid valve: 
Pulmonary valve:   
RVOT:                                                 MPA: 
2 D and DOPPLER HEMODYNAMIC ASSESSMENT: 
Mitral inflow: 
E-wave:        Peak velocity-     DT- 
A-wave:         Peak velocity-                                          TVI-  
E/A ratio: 
TISSUE DOPPLER 
Mitral annular:             E’ velocity-                                   A’ velocity- 
   E/E’ ratio:   MASV   TASV 
E  PROPOGATION VELOCITY 
IVRT: 
IVCT: 
Tricuspid inflow: 
E-wave:        Peak velocity-      DT- 
A-wave:         Peak velocity-                                           TVI-                      
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PATIENT CONSENT FORM 
STUDY TITLE: 
“NEWER ECHOCARDIOGRAPHIC PARAMETERS IN ASSESSING RV AND LV 
FUNCTION IN PATIENTS WITH CORPULMONALE”  
Patient may check () these boxes. 
PARTICIPANT NAME:                                          DATE:                            
 AGE:              SEX:                                    I.P.NO. : 
The details of the study have been provided to me in writing and explained to me in 
my own language. 
I confirm that I have understood the purpose of the above study. I have the 
opportunity to ask the question and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being 
affected. 
I understand that investigator, the institution, regulatory authorities and the ethical 
committee will not need my permission to look at my health records both in respect 
to the current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study. I understand that my identity will not be revealed 
in any information released to third parties or published, unless as required under 
the law. I agree not to restrict the use of any data or results that arise from this 
study.  
 I hereby consent to undergo complete physical examination, and diagnostic tests 
including hematological, biochemical, radiological and urine examinations 
 
I have been given an information sheet giving details of the study. 
I hereby consent to participate in the above study  
                                                                                                                                          
      Signature of the Participant 
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Information to Participants 
Title:   NEWER ECHOCARDIOGRAPHIC PARAMETERS IN ASSESSING RV 
AND LV FUNCTION IN PATIENTS WITH CORPULMONALE 
Principal Investigator: Dr.N.VISWANATHAN 
Co-Investigator (if any): 
Name of Participant: 
Site:   RGGGH& MMC, Chennai 
You are invited to take part in this research/ study/procedures/tests. The information in this document 
is meant to help you decide whether or not to take part. Please feel free to ask if you have any queries 
or concerns. 
What is the purpose of research? 
In patients with COPD not only RV dysfunction but LV diastolic and systolic dysfunction has 
been reported. Newer echocardiographic parameters like tissue Doppler are useful in picking 
early RV & LV dysfunction. The current study aims at using newer echocardiographic 
parameters in assessing RV&LV function in patients with corpulmonale. we have obtained 
permission from the institutional ethics committee.  
The study design 
It is a Retrospective cross-sectional study. 
Study Procedures 
The study involves evaluation of echocardiography newer echocardiographic parameters like 
TAPSE, MAPSE, MASV and propagation velocity in assessing RV and LV function in patients 
with corpulmonale. The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
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Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information (personal 
details, results of physical examinations, investigations, and your medical history). By signing this 
document, you will be allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like the Drug Controller 
General of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific meetings,  
will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or your 
relationship with the investigator or the institution. You will be taken care of and you will not lose 
any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw from this 
study at any time during the course of the study without giving any reasons. However, it is advisable 
that you talk to the research team prior to stopping the treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                                                      Signature of Participant   
Date                                                                                                      Date   
  
ETHICAL COMMITTEE AP
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PROVAL ORDER 
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1 
INTRODUCTION 
In India still pulmonary tuberculosis is prevalent and stays as one 
of the leading cause of death. The cause of the death in most of the 
terminally ill pulmonary tuberculosis patient is corpulmonale and 
related cardiac problem. With the increase in incidence of retro viral 
infection and diabetes the prevalence of multi drug resistant pulmonary 
tuberculosis is high .This leads to increase in the chances for the 
corpulmonale. 
In the rural areas poverty and malnutrition lead to increased 
incidence and prevalence of tuberculosis. In the urban areas exposure to 
the automobile gases and dust particles predisposes patients to 
pulmonary diseases and COPD in later life.  
COPD in the later stages lead to right ventricular dilatation and 
corpulmonale. The development and implementation of the national 
programs for the detection and treatment of the tuberculosis is trying to 
treat the disease in the early stage itself to prevent such corpulmonale in 
future. In this study we are going to find easy solution to diagnose the 
lung disease related cardiac problem in the early stage itself without 
making mistakes.  
